Previous 10 | Next 10 |
home / stock / wxxwy / wxxwy news
WuXi Biologics Statement PR Newswire SHANGHAI , Feb. 7, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unveri...
WuXi Biologics (OTCPK:WXXWY) and South Korea based ImmuneOncia Therapeutics announce that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47. Wit...
UBS highlights its picks in its four next-big-thing sectors: Greentech, 5G+, Fintech and Healthtech. "While this is a longer-term focus, we see attractive investment opportunities in the short to medium term whereby companies benefit from significant fiscal spending following the pandemic as ...
WuXi Biologics Launches a New GMP Commercial Drug Product Facility PR Newswire Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production Increases up to 60 million vials for commercial drug production pe...
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...
WuXi Biologics is the largest biologics outsourcing company in China, and among the top three industry players in the world. The key risks for the stock are geopolitical tensions, policy risks in China, and weaker-than-expected profitability going forward. WuXi Biologics trades at...
WuXi Biologics Reports Strong 2021 Interim Results PR Newswire Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million Adjusted Net Profit Attributable to Owners of the Company Increases...
The rapidly evolving regulatory landscape in China has persistently populated financial market headlines this summer. The cost of raising a larger family can be daunting, particularly as it relates to the “three mountains” of costs associated with childcare – educ...
WuXi Biologics' (OTCPK:WXXWY) Biosafety Testing facility in Suzhou, China has received its second GMP certificate from the European Medicines Agency (EMA). The Biosafety Testing facility received its first EMA GMP certificate just over a year ago. The team offers cell line characterizat...
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate PR Newswire SUZHOU, China , Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced ...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc ADR Company Name:
WXXWY Stock Symbol:
OTCMKTS Market:
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year PR Newswire SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), anno...
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...
WuXi Biologics Receives AAA MSCI ESG Rating PR Newswire SHANGHAI , Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating ...